The recognition of natural plaque mutants of several animal viruses has facilitated the exploration of viral genetics; in some instances plaque characteristics also have been associated with differences in strain virulence and have been exploited for vaccine (9, 20) . Herpesvirus plaque morphology has been used as a biological marker for genetic studies (9, 20) , as well as for discriminating closely related strains (8, 12, 13) . Plaque characteristics of Marek's disease herpesvirus (MDHV) in natural host cells also have proved useful in the preliminary assessment of strain virulence (2, 8) .
Herpesvirus virulence has been associated with a variety of other in vitro properties, including the type of cytopathology, viral growth characteristics at different temperatures, antigenic differences, host cell range, resistance to 5-iododeoxyuridine, and plaque characteristics in alien host cells (8, 9, 11, 16, 21) . Herpesvirus hominis (HVH) types have been studied extensively. With this virus, differences in plaque morphology have permitted the clear discrimination between strains (13, 18 ). An HVH-1 strain that produced small plaques in rabbit kidney cells also was found to be less virulent for rabbits and mice than the wild-type (large-plaque) virus (17) .
Canine herpesvirus (CHV) is an important cause of the deaths of neonatal pups; however, the disease caused by this virus is inapparent in older animals (3, 6) . The dog is the only known host, and viral growth occurs exclusively in cells of canine origin (7, 19) . Growth of CHV is markedly restricted by the temperature of incubation, the optimal range being 35 to 370C (1, 4) . Plaque characteristics of several field isolates grown at optimal temperatures in primary dog kidney cell (DKC) cultures have appeared consistent in size and character (L. N. Binn, personal communication; 15, 19) , with the unique exception of the BR strain (14) 
MATERIALS AND METHODS
Virus strains and cell cultures. Characteristics of CHV (strain F-205) and methods for its cultivation and assay have been described previously (6, 7) . Additional isolates (see Table 1 ) were recovered from tissue specimens submitted for viral culture or, in some instances, were obtained from other investigators. Standard plaque medium for cloning was doublestrength Eagle minimal essential medium (MEM; BBL), supplemented with 10% fetal bovine serum (FBS) and 0.5% lactalbumin hydrolysate (LAH) mixed with an equal volume of 2% agarose (sea plaque). For plaque size determinations and viral assays, monolayer DKC cultures in 60-mm plastic plates were inoculated with 0.2-ml amounts of serial 10-fold dilutions of virus and absorbed for 1.5 h at room temperature. After the adsorption period, 5-ml amounts of MEM, supplemented with 5% FBS and 0.5% LAH that contained 1% methylcellulose (10) , were added to each plate, and cultures then were incubated in a humidified 5% C02 atmosphere at 30 or 350C. After 5 days of incubation, the viscous medium was decanted, and plates were fixed for 10 and then clarified by low-speed centrifugation. The supernatant portions then were placed in cellophane dialysis tubing and dialyzed for 24 h at pH 10.3 (glycine-NaOH buffer) to dissociate viral subunits. After overnight dialysis against 0.15 M phosphate-buffered saline, pH 7.2, the antigen preparation was stored frozen at -70°C. Tests were performed on 2.5-by 7.5-cm plastic immunodiffusion slides, using 0.6% agarose in phosphate-buffered saline. An eight-well pattern was used to compare all permutations of mP or MP antigens with the respective hyperimmune antisera that had been prepared in specific-pathogen-free beagles.
Tests for virulence. A total of 21 specific-pathogen-free beagle pups (four litters) from the Institute's disease-free colony were used. All animals were obtained from bitches without detectable CHV-neutralizing antibody. Serum neutralization methods have been described previously (3). Thirteen neonatal pups (two litters) were given intraperitoneal or oral-nasal inoculations within the first 48 h of birth, since pups rapidly develop resistance to generalized, usually fatal, infections after that time (5) .
To examine effects of immunosuppression on the pathogenicity of the mP variant, eight 2-week-old pups were divided into four groups, each consisting of two pups. In one group, each pup was inoculated with 0.5 ml of goat anti-dog thymocyte serum (ATS) at the time of infection with mP virus and again on postinoculation days 2 and 4. Another group of two pups was given mP virus but no ATS. The third group was inoculated with CHV-MP, and the fourth received CHV-MP plus ATS. Viral doses were 10562 50% tissue culture infective doses (TCID50) (CHV-mP) or 1048 TCID50 (CHV-MP). The ATS, prepared in our laboratory, had a canine lymphocyte cytotoxicity titer of 1:320. After two injections (0.5 ml/kg), there was a marked (>80%) diminution in the normal responses of canine peripheral blood lymphocytes to phytohemagglutinin, severe thymic atrophy, and profound alteration in the course of CHV infection in normally resistant 2-week-old pups (Carmichael, unpublished data (Fig. 2) . When viral inputs were approximately equal, the titers of CHV-mP, after 24 h of growth, were at least 0.8 logo greater than those of the MP strain. CPE of the two strains were similar, but not identical. Cells infected with the mP variant generally were more swollen and refractile than those infected with MP virus, and they tended to clump around the edges of a plaque. Cells infected with the MP strain were uniformly rounded, and they detached readily from the growth surface. Syncytia were not observed with either virus. A consistent feature of the mP variant was the late appearance of CPE in relation to the production of infectious virus. tional difference between the MP virus and the mP variant was the amount of infectious virus released ( Table 2 ). The MP virus was significantly more cell associated throughout the growth period than was the mP variant.
Inactivation at 380C. Results (Fig. 3) suggested that the MP strain is somewhat more heat labile than the MP virus; however, the differences were slight.
Antigenic comparisons. Antisera raised in dogs against the MP field strain (F-205) neutralized the homologous virus and the mP variant to the same extent in plaque reduction and kinetic neutralization tests. Immunodiffusion analysis also failed to reveal antigenic differences, for two precipitin lines of identity were observed between the mP and MP viral antigens and the respective antisera.
Growth of mP and MP strains in splenic macrophage cultures at 30 and 370C. Splenic macrophage cultures maintained at 300C continued to release small amounts of infectious virus (&10 plaque-forming units/0.2 ml) throughout the 70-h incubation period; however, there was scant growth of either virus (Fig. 4) . Growth pups given the MP pups that were given MP virus but not ATS. In Table 4 ); however, contrast, the pups (no. 7 and 8) given MP virus at the time of inoc-and ATS had high viral titers in several organs. ? 4) died by the 6th Remarkably high titers were found in the brain. hat were inoculated Microscopic lesions in the inoculated 2-weekated with ATS did old pups that were given the MP virus but no ever, at necropsy, ATS were disseminated small foci of interstitial Approximately one-pneumonitis, necrosis of occasional hepatocytes, uses from the non-and minute areas of renal hemorrhage and focal pups that received interstitial necrosis, with minimal inflammatory Lacroscopic lesions, changes. Contrasting with these modest lesions as of focal necrosis, were the prominent changes observed in the )served microscopi-MP-inoculated pups treated with ATS (group ne pup (no. 4). The 4). They consisted of interstitial pneumonitis, seen in 2-week-old with alveolar necrosis and hemorrhages, necrotic foci throughout the liver, and multiple foci of necrosis and hemorrhages in the renal cortices, with both tubular and glomerular destruction. at low temperature (300C), a stable mP variant of strain F-205 was the principal viral type. Since cloned mP virus retained the small plaque characteristic after more than 60 passages at 30'C, the mP marker appears to represent a stable biological property inherent to the genome of the variant virus. In these studies, it was found that the mP virus had additional biological properties that distinguished it from the parental MP virus. Notwithstanding the subtle, but nevertheless distinct, differences between the MP and mP strains in the character of cytopathology, the times of onset of CPE, the rates and amounts of virus produced at 30 and 350C, viral persistence in canine spleen monocyte cultures, and, oflesser significance, the rates of inactivation at 380C, there were distinct differences in their virulence for pups.
The MP (wild-type) virus was highly virulent for newborn pups and for 2-week-old animals that had received ATS at the time of infection. The mP variant, however, was clearly an attenuated strain. Although the mP variant persisted for several (4 to 6) days in the nasopharynx, it rarely was recovered from other tissue sites favored by the MP virus, and then only in small amounts.
Association between small plaque size and reduced virulence has been reported for plaque variants or mutants of other herpesviruses (9, 17) , the most noteworthy being MDHV (2, 8, 9) . The mP-CHV, however, did not behave as an attenuated host range, temperature-sensitive mutant, as described for the large-and smallplaque mutants of HVH-2 (9, 11). It did not regularly engender the formation of syncytia, as described for the CHV-BR strain (14) , or occur as a naturally attenuated plaque variant, as described for field isolates of MDHV, but it originated after less than 20 passages in DKC cultures incubated at 30'C after prolonged culture (312 passages) at 35°C. Unfortunately, the precise passage at which the mP variant emerged could not be determined, but it was the dominant type after 20 passages at 300C.
Unlike the antigenic change (loss of the "A antigen") that has been associated with the attenuation of MDHV after prolonged passage in chicken renal cell cultures (16), antigenic markers specific for the attenuated CHV-mP strain were not detected. Further study is necessary to determine the suitability of the mP strain for vaccine purposes.
